Clinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA)

Simple item page
dc.contributor.authorLiu, J.
dc.contributor.authorLee, J.Y.T.
dc.contributor.authorBedrikovetski, S.
dc.contributor.authorTraeger, L.
dc.contributor.authorMoore, J.W.
dc.contributor.authorPerry, J.L.
dc.contributor.authorKroon, H.M.
dc.contributor.authorSammour, T.
dc.date.issued2023
dc.descriptionAvailable online 9 September 2023
dc.description.abstractPathological complete response (pCR) is observed in 11–26% of locally advanced rectal cancers undergoing neoadjuvant chemoradiotherapy (nCRT). This study aims to determine pCR rates and clinicopathological predictors in the Australian and New Zealand (ANZ) cohort. The Bi-National Colorectal Cancer Audit (BCCA) was interrogated for all rectal cancer patients who underwent nCRT prior to surgical resection between 2007 and 2020. Patients were divided in two groups: pCR (AJCC tumour regression grade 0) and partial/no response (pPR, regression grade 1,2 or 3). In total, 3230 patients were included. Rates of pCR and pPR were 704 (21.8%) and 2526 (78.2%), respectively. Long-course nCRT (p < 0.0001), lower clinical tumour stage (cT; p < 0.0001), and nodal stage (cN; p = 0.003) were associated with pCR on univariate analysis. On multivariable analysis, cN0 stage and long-course nCRT remained independent factors for a pCR. Awareness of these predictors provides valuable information when counseling patients regarding prognosis and treatment options.
dc.description.statementofresponsibilityJianliang Liu, Justin Y.T. Lee, Sergei Bedrikovetski, Luke Traeger, James W. Moore, Joanne L. Perry, Hidde M. Kroon, Tarik Sammour
dc.identifier.citationEuropean Journal of Surgical Oncology, 2023; 49(11):107070-1-107070-5
dc.identifier.doi10.1016/j.ejso.2023.107070
dc.identifier.issn0748-7983
dc.identifier.issn1532-2157
dc.identifier.orcidLiu, J. [0000-0001-5520-2011]
dc.identifier.orcidBedrikovetski, S. [0000-0001-9330-625X]
dc.identifier.orcidTraeger, L. [0000-0002-0327-7334]
dc.identifier.orcidKroon, H.M. [0000-0002-8923-7527]
dc.identifier.orcidSammour, T. [0000-0002-4918-8871]
dc.identifier.urihttps://hdl.handle.net/2440/140016
dc.language.isoen
dc.publisherElsevier
dc.rightsCrown Copyright © 2023 Published by Elsevier Ltd. All rights reserved.
dc.source.urihttps://www.sciencedirect.com/science/article/pii/S0748798323007084
dc.subjectRectal cancer; Response; Tumour regression grade; Neoadjuvant therapy; Chemoradiotherapy
dc.subject.meshHumans
dc.subject.meshRectal Neoplasms
dc.subject.meshNeoplasm Staging
dc.subject.meshTreatment Outcome
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshRetrospective Studies
dc.subject.meshAustralia
dc.subject.meshNew Zealand
dc.subject.meshChemoradiotherapy
dc.titleClinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA)
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Surgery publications